Across major Indian cities, stepping into a diagnostics lab typically results in receiving a laminated brochure listing various health packages, rather than a menu of food. The offerings are often divided into tiers: silver, gold, and platinum, featuring packages that include forty, sixty, or even ninety tests, covering everything from fasting blood sugar, thyroid panels, and vitamin D to cardiac markers and tumor markers.
This quiet aspect of India’s healthcare landscape garners less attention compared to the pressing issues of hospital bed shortages or a lack of rural doctors. In urban areas, particularly among the insured and affluent, a different challenge has emerged: excessive testing, often conducted without necessity. Corporate wellness initiatives promote full-body checkups as employee perks, while insurance companies include preventive panels in premium plans as attractive selling points.
Moreover, diagnostic chains frequently announce festive discounts on tests, resembling the sales strategy of electronics retailers. This has led to a situation where healthy individuals exit labs with reports indicating numerous parameters—many flagged in borderline yellow—without a physician present to elucidate their significance.
The Consequences of Overtesting
The implications of such practices are far from trivial. Overtesting can initiate a distressing sequence: a slightly abnormal result on an unnecessary test might prompt a follow-up scan, leading to a biopsy, and resulting in weeks of anxiety over conditions that could very well be harmless.
Healthcare professionals report encountering patients equipped with extensive folders of test results yet lacking any clinical complaint, bewildered by the reasons for their screening but convinced that increased testing equates to improved health.
“The question is not whether early detection saves lives—it does—but whether India’s burgeoning test-industrial complex is confusing detection with reassurance, and reassurance with health,” notes Dr. Haripriya Jagadish, an Internal Medicine Specialist at Apollo Spectra Hospital in Chennai.
Understanding When Tests Are Necessary
When questioned about the necessity of a test, evidence-based practitioners emphasize that the decision should start with an informative dialogue rather than jumping directly to testing.
Dr. Jagadish elaborates, “It’s an individualised question. Most practitioners follow evidence-based guidelines. The doctor will gather a detailed history involving the patient’s symptoms, and tests are then ordered based on this informed context.”
This method of history-taking is often invisible to patients and notably absent from the retail testing model. A physician who assesses a patient’s symptoms, duration, family medical history, and risk factors effectively narrows down possibilities before performing any tests, ensuring that each serves a specific purpose.
Conversely, a preventive package promoted via a billboard bypasses this critical step, offering a plethora of tests without initial inquiries into what the patient’s body may be signaling.
Categories for Indicating Tests
According to Dr. Jagadish, the reasons for indicating a test can generally be categorized into a few clear areas: infections, chronic diseases, inflammation, and malignancy. Each of these is grounded in the presenting symptoms and scientific understanding.
For instance, an unexplained fever may necessitate an infection workup, while unexplained fatigue or weight changes, especially in conjunction with a family history, might justify diabetes or thyroid testing. Localized pain or abnormal findings during an examination could warrant investigation for inflammation or malignancy.
A Regulatory Blind Spot
The regulation surrounding diagnostics in India is significantly behind that of pharmaceuticals. While advertising for prescription drugs requires government oversight, bundled diagnostic tests—including those with serious implications—can often be marketed without similar restrictions.
India does maintain oversight of diagnostic labs focused primarily on technical quality, with accreditation bodies establishing standards for test accuracy. However, there are no regulations regarding the appropriateness of selling tests to asymptomatic customers or mandating pre-test consultation and qualified interpretation of results.
This regulatory gap is not unique; direct-to-consumer testing has surged globally, prompting some countries to impose stricter controls on how aggressively these tests are marketed to healthy populations. Yet, in India, the rapid growth of retail diagnostics has far outpaced regulatory updates, which have stagnated since a time when blood tests required a doctor’s request.
The Anxiety Economy
Often, reports arrive devoid of context—merely a PDF or sheet presenting rows of values, reference ranges, and a handful highlighted in alarming colors without explanations applicable to individual health. For patients lacking symptoms or clinical histories, this ambiguity becomes a breeding ground for anxiety.
The cycle is familiar to clinicians: a mildly elevated tumor marker or a borderline finding on a scan triggers a cascade of follow-up consultations and additional testing, which may escalate to more invasive procedures based on initial findings that could be clinically irrelevant.
As Dr. Jagadish points out, the risk of excessive testing is pertinent. “The issue arises when abnormal values are discovered without medical correlation, as this often causes more harm than good. This generation is particularly susceptible to health-related anxieties, which can increase the overall medical costs for patients as well as their psychological burden.”
This psychological impact rarely comes up in overtesting discussions usually centered on financial waste and clinical inefficiency. However, for patients facing unresolved abnormal results, the experience encompasses more than just administrative challenges—it leads to long periods of uncertainty and stress over factors that might resolve unaided or hold no significant implications.
Ultimately, this narrative underscores a vital truth: not every abnormal finding necessitates action. Medical practice has long recognized that some results are incidental and clinically irrelevant, yet the prevalent model prioritizing tests over a thorough evaluation diminishes the space needed for this crucial understanding. The hidden costs of overtesting are not solely financial; they also encompass the emotional toll experienced by individuals who were never genuinely ill.
